Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
28 Nov 2024: Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline
- Allink Biotherapeutics has successfully raised $42 million in a Series A financing round, led by Lanchi Ventures and supported by new investors such as Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment, along with continued support from existing shareholders Gaorong Ventures and Med-Fine Capital
- The company is focused on developing a diverse pipeline of next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases, with plans to achieve key milestones in the coming months
- The proceeds from the financing will support the global clinical development of the company’s lead ADC candidates, ALK201 and ALK202, in Phase 1 trials across Australia, the U.S., and China
